ProCE Banner Activity

Targeting the MDM2/p53 Signaling Pathway in Biliary Tract Cancers: Rationale and Current Status

Clinical Thought

Get expert insights on the importance of targeting the MDM2/p53 pathway in BTC and the emerging data on targeting this pathway in patients with MDM2-amplified BTC harboring wild-type p53.

Released: August 09, 2024

Expiration: August 08, 2025

Share

Faculty

Patricia LoRusso

Patricia LoRusso, DO, PhD(h)

Associate Center Director, Experimental Therapeutics
Director, Early Phase Clinical Trials Program
Yale Cancer Center
Yale University
New Haven, Connecticut

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Faculty Disclosure

Primary Author

Patricia LoRusso, DO, PhD(h)

Associate Center Director, Experimental Therapeutics
Director, Early Phase Clinical Trials Program
Yale Cancer Center
Yale University
New Haven, Connecticut

Patricia LoRusso, DO, PhD(h): advisor: Actuate Therapeutics, Atreca Development, Boehringer Ingelheim, Cullinan, I-Mab, ImCheck, Kineta, Mekanistic, Mersana, Molecular Templates, NeuroTrials, Qualigen, Quanta Therapeutics, Pfizer, Relay Therapeutics, Seagen, Scenic Biotech, Schrodinger, STCube Pharma, Stemline, Takeda; consultant: I-Mab, Roivant Sciences; data and safety monitoring board: Amgen, DrenBio, Sotio.